Procalcitonin-guided diagnosis and antibiotic stewardship revisited

BMC Medicine

Volumn 15, Issue 1, 2017, Pages

  Sager, Ramon ^a,b   Kutz, Alexander ^a,b   Mueller, Beat ^a,b   Schuetz, Philipp ^a,b  

^a CANTONAL HOSPITAL AARAU   (Switzerland)

^b UNIVERSITY OF BASEL   (Switzerland)

Author keywords

Antibiotic stewardship; Pneumonia; Procalcitonin; Respiratory tract infection; Sepsis

Indexed keywords

ANTIBIOTIC AGENT; PROCALCITONIN; ANTIINFECTIVE AGENT; BIOLOGICAL MARKER; CALCITONIN; CALCITONIN GENE RELATED PEPTIDE; PROTEIN PRECURSOR;

ABDOMINAL DISEASE; ABDOMINAL INFECTION; ANTIBIOTIC STEWARDSHIP; ANTIBIOTIC THERAPY; BACTERIAL ARTHRITIS; BACTERIAL INFECTION; BACTERIAL PNEUMONIA; BLOODSTREAM INFECTION; CLINICAL RESEARCH; CONGESTIVE HEART FAILURE; CRITICALLY ILL PATIENT; DIAGNOSTIC VALUE; DISEASE MARKER; DISEASE SEVERITY; DRUG SAFETY; DRUG TREATMENT FAILURE; ENDOCARDITIS; ERYSIPELAS; FEBRILE NEUTROPENIA; HOSPITAL ADMISSION; HUMAN; MEDICAL DECISION MAKING; MENINGITIS; META ANALYSIS (TOPIC); MORTALITY; NONHUMAN; PATIENT CARE; PATIENT MONITORING; POSTOPERATIVE INFECTION; PROGNOSIS; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENT INFECTION; RESPIRATORY TRACT INFECTION; SENSITIVITY AND SPECIFICITY; SEPSIS; SEPTIC SHOCK; SHORT SURVEY; TREATMENT DURATION; URINARY TRACT INFECTION; BACTERIAL INFECTIONS; TREATMENT FAILURE;

ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; BIOMARKERS; CALCITONIN; CALCITONIN GENE-RELATED PEPTIDE; HUMANS; PROTEIN PRECURSORS; TREATMENT FAILURE;

EID: 85010715713     PISSN: None     EISSN: 17417015     Source Type: Journal    
DOI: 10.1186/s12916-017-0795-7     Document Type: Short Survey

References (94)

1. Mitsuma SF, Mansour MK, Dekker JP, Kim J, Rahman MZ, Tweed-Kent A, Schuetz P. Promising new assays and technologies for the diagnosis and management of infectious diseases. Clin Infectious Dis. 2013;56(7):996-1002.
2. Schuetz P, Albrich W, Mueller B. Procalcitonin for diagnosis of infection and guide to antibiotic decisions: past, present and future. BMC Med. 2011;9:107.
3. Musher DM, Thorner AR. Community-acquired pneumonia. New Engl J Med. 2014;371(17):1619-28.
4. Fiumefreddo R, Zaborsky R, Haeuptle J, Christ-Crain M, Trampuz A, Steffen I, Frei R, Muller B, Schuetz P. Clinical predictors for Legionella in patients presenting with community-acquired pneumonia to the emergency department. BMC Pulm Med. 2009;9:4.
5. Haubitz S, Hitz F, Graedel L, Batschwaroff M, Wiemken TL, Peyrani P, Ramirez JA, Fux CA, Mueller B, Schuetz P. Ruling out Legionella in community-acquired pneumonia. Am J Med. 2014;127(10):1010. e1011-19.
6. Schuetz P, Muller B, Christ-Crain M, Stolz D, Tamm M, Bouadma L, Luyt CE, Wolff M, Chastre J, Tubach F, et al. Procalcitonin to initiate or discontinue antibiotics in acute respiratory tract infections. Cochrane Database Syst Rev. 2012;9(9), CD007498.
7. Schuetz P, Briel M, Christ-Crain M, Stolz D, Bouadma L, Wolff M, Luyt CE, Chastre J, Tubach F, Kristoffersen KB, et al. Procalcitonin to guide initiation and duration of antibiotic treatment in acute respiratory infections: an individual patient data meta-analysis. Clin Infect Dis. 2012;55(5):651-62.
8. Schuetz P, Christ-Crain M, Thomann R, Falconnier C, Wolbers M, Widmer I, Neidert S, Fricker T, Blum C, Schild U, et al. Effect of procalcitonin-based guidelines vs standard guidelines on antibiotic use in lower respiratory tract infections: the ProHOSP randomized controlled trial. JAMA. 2009;302(10):1059-66.
9. Schuetz P, Chiappa V, Briel M, Greenwald JL. Procalcitonin algorithms for antibiotic therapy decisions: a systematic review of randomized controlled trials and recommendations for clinical algorithms. Arch Inter Med. 2011;171(15):1322-31.
10. Schuetz P, Briel M, Mueller B. Clinical outcomes associated with procalcitonin algorithms to guide antibiotic therapy in respiratory tract infections. JAMA. 2013;309(7):717-8.
11. Woodhead M, Blasi F, Ewig S, Garau J, Huchon M, Leven M, Ortqvist A, Schaberg T, Torres A, Read R, et al. Guidelines for the management of adult lower respiratory tract infections. Clin Microbiol Infect. 2011;17 Suppl 6:E1-E59.
12. Corti C, Fally M, Fabricius-Bjerre A, Mortensen K, Jensen BN, Andreassen HF, Porsbjerg C, Knudsen JD, Jensen JU. Point-of-care procalcitonin test to reduce antibiotic exposure in patients hospitalized with acute exacerbation of COPD. Int J Chron Obstruct Pulmon Dis. 2016;11:1381-9.
13. Kutz A, Hausfater P, Oppert M, Alan M, Grolimund E, Gast C, Alonso C, Wissmann C, Kuehn C, Bernard M, et al. Comparison between B.R.A.H.M.S PCT direct, a new sensitive point-of-care testing device for rapid quantification of procalcitonin in emergency department patients and established reference methods - a prospective multinational trial. Clin Chem Lab Med. 2016;54(4):577-84.
14. Bafadhel M, Clark TW, Reid C, Medina MJ, Batham S, Barer MR, Nicholson KG, Brightling CE. Procalcitonin and C-reactive protein in hospitalized adult patients with community-acquired pneumonia or exacerbation of asthma or COPD. Chest. 2011;139(6):1410-8.
15. Ding J, Chen Z, Feng K. Procalcitonin-guided antibiotic use in acute exacerbations of idiopathic pulmonary fibrosis. Int J Med Sci. 2013;10(7):903-7.
16. Dusemund F, Bucher B, Meyer S, Thomann R, Kuhn F, Bassetti S, Sprenger M, Baechli E, Sigrist T, Schwietert M, et al. Influence of procalcitonin on decision to start antibiotic treatment in patients with a lower respiratory tract infection: insight from the observational multicentric ProREAL surveillance. Eur J Clin Microbiol Infect Dis. 2013;32(1):51-60.
17. Vincent JL, Sakr Y, Sprung CL, Ranieri VM, Reinhart K, Gerlach H, Moreno R, Carlet J, Le Gall JR, Payen D, et al. Sepsis in European intensive care units: results of the SOAP study. Crit Care Med. 2006;34(2):344-53.
18. Balk RA, Kadri SS, Cao Z, Robinson SB, Lipkin C, Bozzette SA. Effect of procalcitonin testing on healthcare utilization and costs in critically ill patients in the United States. Chest. 2017;151(1):23-33.
19. Laukemann S, Kasper N, Kulkarni P, Steiner D, Rast AC, Kutz A, Felder S, Haubitz S, Faessler L, Huber A, et al. Can we reduce negative blood cultures with clinical scores and blood markers? Results from an observational cohort study. Medicine (Baltimore). 2015;94(49), e2264.
20. Yu Y, Li XX, Jiang LX, Du M, Liu ZG, Cen ZR, Wang H, Guo ZH, Chang P. Procalcitonin levels in patients with positive blood culture, positive body fluid culture, sepsis, and severe sepsis: a cross-sectional study. Infect Dis (Lond). 2016;48(1):63-9.
21. Wacker C, Prkno A, Brunkhorst FM, Schlattmann P. Procalcitonin as a diagnostic marker for sepsis: a systematic review and meta-analysis. Lancet Infect Dis. 2013;13(5):426-35.
22. Jeong S, Park Y, Cho Y, Kim HS. Diagnostic utilities of procalcitonin and C-reactive protein for the prediction of bacteremia determined by blood culture. Clin Chim Acta. 2012;413(21-22):1731-6.
23. Hoenigl M, Raggam RB, Wagner J, Prueller F, Grisold AJ, Leitner E, Seeber K, Prattes J, Valentin T, Zollner-Schwetz I, et al. Procalcitonin fails to predict bacteremia in SIRS patients: a cohort study. Int J Clin Pract. 2014;68(10):1278-81.
24. Oksuz L, Somer A, Salman N, Erk O, Gurler N. Procalcitonin and C-reactive protein in differantiating to contamination from bacteremia. Braz J Microbiol. 2014;45(4):1415-21.
25. Mencacci A, Leli C, Cardaccia A, Meucci M, Moretti A, D'Alo F, Farinelli S, Pagliochini R, Barcaccia M, Bistoni F. Procalcitonin predicts real-time PCR results in blood samples from patients with suspected sepsis. PLoS One. 2012;7(12), e53279.
26. Guo SY, Zhou Y, Hu QF, Yao J, Wang H. Procalcitonin is a marker of Gram-negative bacteremia in patients with sepsis. Am J Med Sci. 2015;349(6):499-504.
27. Anand D, Das S, Bhargava S, Srivastava LM, Garg A, Tyagi N, Taneja S, Ray S. Procalcitonin as a rapid diagnostic biomarker to differentiate between culture-negative bacterial sepsis and systemic inflammatory response syndrome: a prospective, observational, cohort study. J Crit Care. 2015;30(1):218e7-218e12.
28. Tian G, Pan SY, Ma G, Liao W, Su QG, Gu BC, Qin K. Serum levels of procalcitonin as a biomarker for differentiating between sepsis and systemic inflammatory response syndrome in the neurological intensive care unit. J Clin Sci. 2014;21(7):1153-8.
29. Prkno A, Wacker C, Brunkhorst FM, Schlattmann P. Procalcitonin-guided therapy in intensive care unit patients with severe sepsis and septic shock--a systematic review and meta-analysis. Crit Care. 2013;17(6):R291.
30. de Jong E, van Oers JA, Beishuizen A, Vos P, Vermeijden WJ, Haas LE, Loef BG, Dormans T, van Melsen GC, Kluiters YC, et al. Efficacy and safety of procalcitonin guidance in reducing the duration of antibiotic treatment in critically ill patients: a randomised, controlled, open-label trial. Lancet Infect Dis. 2016;16(7):819-27.
31. Schuetz P, Mueller B. Procalcitonin in critically ill patients: time to change guidelines and antibiotic use in practice. Lancet Infect Dis. 2016;16(7):758-60.
32. Bloos F, Trips E, Nierhaus A, Briegel J, Heyland DK, Jaschinski U, Moerer O, Weyland A, Marx G, Grundling M, et al. Effect of sodium selenite administration and procalcitonin-guided therapy on mortality in patients with severe sepsis or septic shock: a randomized clinical trial. JAMA Intern Med. 2016;176(9):1266-76.
33. Shehabi Y, Sterba M, Garrett PM, Rachakonda KS, Stephens D, Harrigan P, Walker A, Bailey MJ, Johnson B, Millis D, et al. Procalcitonin algorithm in critically ill adults with undifferentiated infection or suspected sepsis. A randomized controlled trial. Am J Resp Crit Care Med. 2014;190(10):1102-10.
34. Wang T, Cui YL, Chu ZX, Liu J, Ban Y, Li TS. Value of a model based on PIRO conception in predicting the prognosis in critical patients. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2013;25(12):729-33.
35. Zhao Y, Li C, Jia Y. Evaluation of the Mortality in Emergency Department Sepsis score combined with procalcitonin in septic patients. Am J Emerg Med. 2013;31(7):1086-91.
36. Hattori T, Nishiyama H, Kato H, Ikegami S, Nagayama M, Asami S, Usami M, Suzuki M, Murakami I, Minoshima M, et al. Clinical value of procalcitonin for patients with suspected bloodstream infection. Am J Clin Pathol. 2014;141(1):43-51.
37. Heredia-Rodriguez M, Bustamante-Munguira J, Fierro I, Lorenzo M, Jorge-Monjas P, Gomez-Sanchez E, Alvarez FJ, Bergese SD, Eiros JM, Bermejo-Martin JF, et al. Procalcitonin cannot be used as a biomarker of infection in heart surgery patients with acute kidney injury. J Crit Care. 2016;33:233-9.
38. Maisel A, Neath SX, Landsberg J, Mueller C, Nowak RM, Peacock WF, Ponikowski P, Mockel M, Hogan C, Wu AH, et al. Use of procalcitonin for the diagnosis of pneumonia in patients presenting with a chief complaint of dyspnoea: results from the BACH (Biomarkers in Acute Heart Failure) trial. Eur J Heart Fail. 2012;14(3):278-86.
39. Demissei BG, Cleland JG, O'Connor CM, Metra M, Ponikowski P, Teerlink JR, Davison B, Givertz MM, Bloomfield DM, Dittrich H, et al. Procalcitonin-based indication of bacterial infection identifies high risk acute heart failure patients. Int J Cardiol. 2016;204:164-71.
40. Wang W, Zhang X, Ge N, Liu J, Yuan H, Zhang P, Liu W, Wen D. Procalcitonin testing for diagnosis and short-term prognosis in bacterial infection complicated by congestive heart failure: a multicenter analysis of 4,698 cases. Crit Care. 2014;18(1):R4.
41. Schuetz P, Daniels LB, Kulkarni P, Anker SD, Mueller B. Procalcitonin: A new biomarker for the cardiologist. Int J Cardiol. 2016;223:390-7.
42. Albrich WC, Dusemund F, Bucher B, Meyer S, Thomann R, Kuhn F, Bassetti S, Sprenger M, Bachli E, Sigrist T, et al. Effectiveness and safety of procalcitonin-guided antibiotic therapy in lower respiratory tract infections in "real life": an international, multicenter poststudy survey (ProREAL). Arch Intern Med. 2012;172(9):715-22.
43. Schuetz P, Kutz A, Grolimund E, Haubitz S, Demann D, Vogeli A, Hitz F, Christ-Crain M, Thomann R, Falconnier C, et al. Excluding infection through procalcitonin testing improves outcomes of congestive heart failure patients presenting with acute respiratory symptoms: results from the randomized ProHOSP trial. Int J Cardiol. 2014;175(3):464-72.
44. Julian-Jimenez A, Gutierrez-Martin P, Lizcano-Lizcano A, Lopez-Guerrero MA, Barroso-Manso A, Heredero-Galvez E. Usefulness of procalcitonin and C-reactive protein for predicting bacteremia in urinary tract infections in the emergency department. Actas Urol Esp. 2015;39(8):502-10.
45. Lee H, Lee YS, Jeong R, Kim YJ, Ahn S. Predictive factors of bacteremia in patients with febrile urinary tract infection: an experience at a tertiary care center. Infection. 2014;42(4):669-74.
46. Hosokawa Y, Takenaga M, Itami Y, Shinohara M, Takada S, Hayashi Y, Hashimura M, Fujimoto K, Hirao Y. [Clinical utility of measurement of procalcitonin for diagnosis of urosepsis]. Hinyokika Kiyo. 2012;58(10):539-42.
47. Drozdov D, Schwarz S, Kutz A, Grolimund E, Rast AC, Steiner D, Regez K, Schild U, Guglielmetti M, Conca A, et al. Procalcitonin and pyuria-based algorithm reduces antibiotic use in urinary tract infections: a randomized controlled trial. BMC Med. 2015;13:104.
48. Bouaicha S, Blatter S, Moor BK, Spanaus K, Dora C, Werner CM. Early serum procalcitonin level after primary total hip replacement. Mediators Inflamm. 2013;2013:927636.
49. Amin DN, Pruitt JC, Schuetz P. Influence of major cardiopulmonary surgery on serum levels of procalcitonin and other inflammatory markers. Anaesth Intensive Care. 2012;40(5):760-6.
50. Varetto G, Castagno C, Trucco A, Frola E, Bert F, Scozzari G, Rispoli P. Serum procalcitonin as a valuable diagnostic tool in the early detection of infectious complications after open abdominal aortic repair. Annals Vasc Surg. 2016;34:111-8.
51. Kaido T, Ogawa K, Fujimoto Y, Mori A, Hatano E, Okajima H, Uemoto S. Perioperative changes of procalcitonin levels in patients undergoing liver transplantation. Transpl Infect Dis. 2014;16(5):790-6.
52. Kallel S, Abid M, Jarraya A, Abdenadher M, Mnif E, Frikha I, Ayadi F, Karoui A. Kinetics, diagnostic and prognostic value of procalcitonin after cardiac surgery. Ann Biol Clin. 2012;70(5):567-80.
53. Dong Z, Jianxin Z, Haraguchi G, Arai H, Mitaka C. Procalcitonin for the differential diagnosis of infectious and non-infectious systemic inflammatory response syndrome after cardiac operation. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2014;26(7):478-9.
54. Friederichs J, Hutter M, Hierholzer C, Novotny A, Friess H, Buhren V, Hungerer S. Procalcitonin ratio as a predictor of successful surgical treatment of severe necrotizing soft tissue infections. Am J Surg. 2013;206(3):368-73.
55. Suarez-de-la-Rica A, Maseda E, Anillo V, Tamayo E, Garcia-Bernedo CA, Ramasco F, Hernandez-Gancedo C, Lopez-Tofino A, Gimenez MJ, Granizo JJ, et al. Biomarkers (procalcitonin, C reactive protein, and lactate) as predictors of mortality in surgical patients with complicated intra-abdominal infection. Surg Infect. 2015;16(3):346-51.
56. Amin DN, Pruitt JC, Schuetz P. Influence of major cardiopulmonary surgery on serum levels of procalcitonin and other inflammatory markers. Anaesthesia and intensive care. 2012;40(5):760-6.
57. Dominguez-Comesana E, Lopez-Gomez V, Estevez-Fernandez SM, Marino Padin E, Ballinas-Miranda J, Carrera-Dacosta E, Pinon-Cimadevila MA, Barreiro-Morandeira F. Procalcitonin and C-reactive protein as early indicators of postoperative intra-abdominal infection after surgery for gastrointestinal cancer. Cir Esp. 2014;92(4):240-6.
58. Cousin F, Ortega-Deballon P, Bourredjem A, Doussot A, Giaccaglia V, Fournel I. Diagnostic accuracy of procalcitonin and C-reactive protein for the early diagnosis of intra-abdominal infection after elective colorectal surgery: a meta-analysis. Ann Surg. 2016;264(2):252-6.
59. Facy O, Paquette B, Orry D, Binquet C, Masson D, Bouvier A, Fournel I, Charles PE, Rat P, Ortega-Deballon P. Diagnostic accuracy of inflammatory markers as early predictors of infection after elective colorectal surgery: results from the IMACORS Study. Ann Surg. 2016;263(5):961-6.
60. Villarreal E, Vacacela K, Gordon M, Calabuig C, Alonso R, Ruiz J, Kot P, Babiloni D, Ramirez P. Usefulness of procalcitonin for diagnosing infection in critically ill patients with liver cirrhosis. Med Intensiva. 2016;40(2):84-9.
61. Cai ZH, Fan CL, Zheng JF, Zhang X, Zhao WM, Li B, Li L, Dong PL, Ding HG. Measurement of serum procalcitonin levels for the early diagnosis of spontaneous bacterial peritonitis in patients with decompensated liver cirrhosis. BMC Infect Dis. 2015;15:55.
62. Staubli SM, Oertli D, Nebiker CA. Laboratory markers predicting severity of acute pancreatitis. Crit Rev Clin Lab Sci. 2015;52(6):273-83.
63. Woo SM, Noh MH, Kim BG, Hsing CT, Han JS, Ryu SH, Seo JM, Yoon HA, Jang JS, Choi SR, et al. Comparison of serum procalcitonin with Ranson, APACHE-II, Glasgow and Balthazar CT severity index scores in predicting severity of acute pancreatitis. Korean J Gastroenterol. 2011;58(1):31-7.
64. Yamashita H, Yuasa N, Takeuchi E, Goto Y, Miyake H, Miyata K, Kato H, Ito M. Diagnostic value of procalcitonin for acute complicated appendicitis. Nagoya J Med Sci. 2016;78(1):79-88.
65. Qu R, Ji Y, Ling Y, Ye CY, Yang SM, Liu YY, Yang RY, Luo YF, Guo Z. Procalcitonin is a good tool to guide duration of antibiotic therapy in patients with severe acute pancreatitis. A randomized prospective single-center controlled trial. Saudi Med J. 2012;33(4):382-7.
66. Maseda E, Suarez-de-la-Rica A, Anillo V, Tamayo E, Garcia-Bernedo CA, Ramasco F, Villagran MJ, Maggi G, Gimenez MJ, Aguilar L, et al. Procalcitonin-guided therapy may reduce length of antibiotic treatment in intensive care unit patients with secondary peritonitis: a multicenter retrospective study. J Crit Care. 2015;30(3):537-42.
67. Yu CW, Juan LI, Hsu SC, Chen CK, Wu CW, Lee CC, Wu JY. Role of procalcitonin in the diagnosis of infective endocarditis: a meta-analysis. Am J Emerg Med. 2013;31(6):935-41.
68. Cornelissen CG, Frechen DA, Schreiner K, Marx N, Kruger S. Inflammatory parameters and prediction of prognosis in infective endocarditis. BMC Infect Dis. 2013;13:272.
69. Fu Y, Jiang H, Li LX, Chen J, Zhang JL, Wang LL. Application value of procalcitonin and immune inflammatory factors for prediction of bacteraemia in patients with hematologic malignancy combined with febrile neutropenia. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2013;21(5):1296-300.
70. Liu X, Wang DF, Fang Y, Ye WF, Liu S, Lou N. Initial procalcitonin level predicts infection and its outcome in patients with non-Hodgkin lymphoma with febrile neutropenia. Leuk Lymphoma. 2015;56(1):85-91.
71. Wu CW, Wu JY, Chen CK, Huang SL, Hsu SC, Lee MT, Chang SS, Lee CC. Does procalcitonin, C-reactive protein, or interleukin-6 test have a role in the diagnosis of severe infection in patients with febrile neutropenia? A systematic review and meta-analysis. Support Care Cancer. 2015;23(10):2863-72.
72. Marc E, Menager C, Moulin F, Stos B, Chalumeau M, Guerin S, Lebon P, Brunet F, Raymond J, Gendrel D. Procalcitonin and viral meningitis: reduction of unnecessary antibiotics by measurement during an outbreak. Arch Pediatr. 2002;9(4):358-64.
73. Vikse J, Henry BM, Roy J, Ramakrishnan PK, Tomaszewski KA, Walocha JA. The role of serum procalcitonin in the diagnosis of bacterial meningitis in adults: a systematic review and meta-analysis. Int J Infect Dis. 2015;38:68-76.
74. Wei TT, Hu ZD, Qin BD, Ma N, Tang QQ, Wang LL, Zhou L, Zhong RQ. Diagnostic accuracy of procalcitonin in bacterial meningitis versus nonbacterial meningitis: a systematic review and meta-analysis. Medicine. 2016;95(11), e3079.
75. Kim J, Kim SE, Park BS, Shin KJ, Ha SY, Park J, Park KM. Procalcitonin as a diagnostic and prognostic factor for tuberculosis meningitis. J Clin Neurol. 2016;12(3):332-9.
76. Paosong S, Narongroeknawin P, Pakchotanon R, Asavatanabodee P, Chaiamnuay S. Serum procalcitonin as a diagnostic aid in patients with acute bacterial septic arthritis. Int J Rheum Dis. 2015;18(3):352-9.
77. Zhang J, Liu J, Long L, Zhou Q, Cheng J, Zhou B. Value of procalcitonin measurement in the diagnosis of bacterial infections in patients with fever and flare of chronic gouty arthritis. Zhonghua Yi Xue Za Zhi. 2015;95(31):2556-9.
78. Liu W, Sigdel KR, Wang Y, Su Q, Huang Y, Zhang YL, Chen J, Duan L, Shi G. High level serum procalcitonin associated gouty arthritis susceptibility: from a Southern Chinese Han population. PLoS One. 2015;10(7), e0132855.
79. Sato H, Tanabe N, Murasawa A, Otaki Y, Sakai T, Sugaya T, Ito S, Otani H, Abe A, Ishikawa H, et al. Procalcitonin is a specific marker for detecting bacterial infection in patients with rheumatoid arthritis. J Rheumatol. 2012;39(8):1517-23.
80. Wang C, Zhong D, Liao Q, Kong L, Liu A, Xiao H. Procalcitonin levels in fresh serum and fresh synovial fluid for the differential diagnosis of knee septic arthritis from rheumatoid arthritis, osteoarthritis and gouty arthritis. Exp Ther Med. 2014;8(4):1075-80.
81. Rast AC, Knobel D, Faessler L, Kutz A, Felder S, Laukemann S, Steiner D, Haubitz S, Fux CA, Huber A, et al. Use of procalcitonin, C-reactive protein and white blood cell count to distinguish between lower limb erysipelas and deep vein thrombosis in the emergency department: a prospective observational study. J Dermatol. 2015;42(8):778-85.
82. Meili M, Kutz A, Briel M, Christ-Crain M, Bucher HC, Mueller B, Schuetz P. Infection biomarkers in primary care patients with acute respiratory tract infections-comparison of procalcitonin and C-reactive protein. BMC Pulm Med. 2016;16(1):43.
83. Meili M, Muller B, Kulkarni P, Schutz P. Management of patients with respiratory infections in primary care: procalcitonin, C-reactive protein or both? Expert Rev Respir Med. 2015;9(5):587-601.
84. Christ-Crain M, Muller B. Procalcitonin in bacterial infections--hype, hope, more or less? Swiss Med Wkly. 2005;135(31-32):451-60.
85. Uzzan B, Cohen R, Nicolas P, Cucherat M, Perret GY. Procalcitonin as a diagnostic test for sepsis in critically ill adults and after surgery or trauma: a systematic review and meta-analysis. Crit Care Med. 2006;34(7):1996-2003.
86. Hunziker S, Hugle T, Schuchardt K, Groeschl I, Schuetz P, Mueller B, Dick W, Eriksson U, Trampuz A. The value of serum procalcitonin level for differentiation of infectious from noninfectious causes of fever after orthopaedic surgery. J Bone Joint Surg. 2010;92(1):138-48.
87. Schuetz P, Balk R, Briel M, Kutz A, Christ-Crain M, Stolz D, Bouadma L, Wolff M, Kristoffersen KB, Wei L, et al. Economic evaluation of procalcitonin-guided antibiotic therapy in acute respiratory infections: a US health system perspective. Clin Chem Lab Med. 2015;53(4):583-92.
88. Whitney CG, Farley MM, Hadler J, Harrison LH, Lexau C, Reingold A, Lefkowitz L, Cieslak PR, Cetron M, Zell ER, et al. Increasing prevalence of multidrug-resistant Streptococcus pneumoniae in the United States. New Engl J Med. 2000;343(26):1917-24.
89. Long W, Li LJ, Huang GZ, Zhang XM, Zhang YC, Tang JG, Zhang Y, Lu G. Procalcitonin guidance for reduction of antibiotic use in patients hospitalized with severe acute exacerbations of asthma: a randomized controlled study with 12-month follow-up. Crit Care. 2014;18(5):471.
90. Burkhardt O, Ewig S, Haagen U, Giersdorf S, Hartmann O, Wegscheider K, Hummers-Pradier E, Welte T. Procalcitonin guidance and reduction of antibiotic use in acute respiratory tract infection. Eur Respir J. 2010;36(3):601-7.
91. Briel M, Schuetz P, Mueller B, Young J, Schild U, Nusbaumer C, Periat P, Bucher HC, Christ-Crain M. Procalcitonin-guided antibiotic use vs a standard approach for acute respiratory tract infections in primary care. Arch Intern Med. 2008;168(18):2000-7. discussion 2007-8.
92. Yu CW, Juan LI, Wu MH, Shen CJ, Wu JY, Lee CC. Systematic review and meta-analysis of the diagnostic accuracy of procalcitonin, C-reactive protein and white blood cell count for suspected acute appendicitis. Br J Surg. 2013;100(3):322-9.
93. Lima SS, Nobre V, de Castro Romanelli RM, Clemente WT, da Silva Bittencourt HN, Melo AC, Salomao LC, Serufo JC. Procalcitonin-guided protocol is not useful to manage antibiotic therapy in febrile neutropenia: a randomized controlled trial. Ann Hematol. 2016;95(7):1169-76.
94. Tsujimoto K, Hata A, Fujita M, Hatachi S, Yagita M. Presepsin and procalcitonin as biomarkers of systemic bacterial infection in patients with rheumatoid arthritis. Int J Rheum Dis. 2016 [Epub ahead of print].